Platelet Transfusion Refractoriness (ACERTP)

Institut de cancérologie Strasbourg Europe

Status: Completed

Conditions: Platelet Transfusion Refractoriness

Treatments: Procedure: platelet transfusion

Study type: Observational

Funder types: Other

Identifiers

NCT05399693

2021-006

Details and patient eligibility

About

Platelet Transfusion Refractoriness is one of the severe complications after multiple transfusions in patients with severe thrombopenia. Platelet Transfusion Refractoriness is characterized by inefficient transfusion and arise from allo-antibodies specific of platelets antigenes, mostly carried by HLA-I molecules.

Full description

A preliminary study has shown different isotypes of anti-HLA I in patients with Platelet Transfusion Refractoriness. Our hypothesis is that the type of anti-HLA I antibodies (recognised epitope, quantity, isotype) should establish predictive and diagnostic criteria for Platelet Transfusion Refractoriness.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient with Hematopoietic stem cells graft (autograft or allograft) or with acute leukemia with the indication of platelet transfusion.

Exclusion criteria

• Patient under guardianship
• Minor patient

Trial design

50 participants in 2 patient groups

Patients with Platelet Transfusion Refractoriness

Treatment:

Procedure: platelet transfusion

Patients without Platelet Transfusion Refractoriness

Treatment:

Procedure: platelet transfusion